Plaza-Diaz Julio, Ruiz-Ojeda Francisco Javier, López-Plaza Bricia, Brandimonte-Hernández Marco, Álvarez-Mercado Ana Isabel, Arcos-Castellanos Lucía, Feliú-Batlle Jaime, Hummel Thomas, Palma-Milla Samara, Gil Angel
Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitalario Universitario de Granada, 18014 Granada, Spain.
Cancers (Basel). 2024 Oct 8;16(19):3414. doi: 10.3390/cancers16193414.
BACKGROUND/OBJECTIVES: Dysgeusia contributes to the derangement of nutritional status in patients with cancer as well as worsening the quality of life. There has been a lack of effective treatments for taste disorders provided by the pharmaceutical industry.
This was a pilot randomized, parallel, triple-blind, and placebo-controlled intervention clinical trial in which 31 malnourished patients with cancer and dysgeusia receiving antineoplastic treatment were randomized into three arms [standard dose of DMB (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet) or placebo (300 mg freeze-dried strawberry)] for three months. Patients consumed a DMB or placebo tablet before each main meal. Using the nanopore methodology, we analyzed the oral microbiome of patients with cancer using saliva samples.
All patients with cancer and dysgeusia had dysbiosis in terms of lower bacterial diversity and richness. DMB consumption was associated with changes in oral microbiome composition. Neither selected bacteria nor taste perception, type of diet, and cytokine levels were associated with mucositis. Likewise, alcohol and tobacco consumption as well as general and digestive toxicity due to systemic therapy were not associated with specific changes of the oral microbiome, according to logistic binary regression. The standard dose of DMB resulted in a lower abundance of compared with the high DMB dose and placebo at 3 months after intervention with DMB. In particular, some species such as , , and were less abundant in the DMB standard-dose group. Additionally, the consumption of a standard dose of DMB revealed a negative association between the concentrations of TNF-α and the abundance of species such as , , and .
Accordingly, regular DMB consumption could modify the oral microbiome in patients with cancer and dysgeusia, which may contribute to maintaining an appropriate immune response. However, as the present pilot study involved a small number of participants, further studies are necessary to draw robust conclusions from the data.
背景/目的:味觉障碍会导致癌症患者营养状况紊乱,并降低生活质量。制药行业一直缺乏针对味觉障碍的有效治疗方法。
这是一项试点随机、平行、三盲、安慰剂对照干预临床试验,31名接受抗肿瘤治疗且患有味觉障碍的营养不良癌症患者被随机分为三组[标准剂量的二甲基苄基氯化铵(150毫克二甲基苄基氯化铵/片)、高剂量的二甲基苄基氯化铵(300毫克二甲基苄基氯化铵/片)或安慰剂(300毫克冻干草莓)],为期三个月。患者在每餐主餐前服用一片二甲基苄基氯化铵或安慰剂。我们使用纳米孔方法,通过唾液样本分析癌症患者的口腔微生物群。
所有患有味觉障碍的癌症患者在细菌多样性和丰富度方面均存在生态失调。服用二甲基苄基氯化铵与口腔微生物群组成的变化有关。所选细菌、味觉感知、饮食类型和细胞因子水平均与口腔炎无关。同样,根据逻辑二元回归分析,饮酒、吸烟以及全身治疗引起的全身和消化毒性与口腔微生物群的特定变化无关。干预二甲基苄基氯化铵三个月后,与高剂量二甲基苄基氯化铵和安慰剂相比,标准剂量的二甲基苄基氯化铵导致 的丰度较低。特别是,二甲基苄基氯化铵标准剂量组中某些物种如 、 和 的丰度较低。此外,服用标准剂量的二甲基苄基氯化铵显示肿瘤坏死因子-α浓度与 、 、 和 等物种的丰度之间存在负相关。
因此,定期服用二甲基苄基氯化铵可能会改变患有味觉障碍的癌症患者的口腔微生物群,这可能有助于维持适当的免疫反应。然而,由于本试点研究涉及的参与者数量较少,需要进一步研究才能从数据中得出有力结论。